Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
mTORC1/2抑制剂Sapanisertib(CB-228/TAK-228)联合二甲双胍治疗mTOR/AKT/PI3K通路改变和晚期实体恶性肿瘤患者的I期研究
期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-22-0260
Subbiah, Vivek; Coleman, Niamh; Piha-Paul, Sarina A; Tsimberidou, Apostolia M; Janku, Filip; Rodon, Jordi; Pant, Shubham; Dumbrava, Ecaterina E Ileana; Fu, Siqing; Hong, David S; Zhang, Shizhen; Sun, Ming; Jiang, Yunfang; Roszik, Jason; Song, Juhee; Yuan, Ying; Meric-Bernstam, Funda; Naing, Aung